Moderna and Merck's Cancer Vaccine Breakthrough Ignites Biotech Boom

The biotech sector has found a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc's (NYSE:MRK) positive Phase 3 results for their personalized mRNA cancer vaccine have sparked investor interest in genomics, immunotherapy, and precision medicine ETFs.

The companies' intismeran autogene therapy, combined with Merck's Keytruda, significantly improved recurrence-free and distant metastasis-free survival in patients with resected stage IIB-IV melanoma. This is the first mRNA-based cancer therapy to post a positive Phase 3 result.

Moderna uses AI tools to help identify promising neoantigens, linking the cancer-vaccine opportunity to the broader genomics and precision-medicine ecosystem. Investors can tap into this trend through targeted ETFs like the iShares Genomics Immunology and Healthcare ETF (NYSE:IDNA), which holds both Moderna and Merck.

The ARK Genomic Revolution ETF (BATS:ARKG) offers a more aggressive genomics angle, with holdings including Twist Bioscience Corp (NASDAQ:TWST), 10x Genomics Inc (NASDAQ:TXG), and CRISPR Therapeutics (NASDAQ:CRSP). This fund provides exposure to genetic sequencing, molecular diagnostics, and gene-editing technologies that could support personalized medicine.

For those seeking less concentrated exposure, the SPDR S&P Biotech ETF (NYSE:XBI) holds Moderna at about 2.8% of assets, while the iShares Biotechnology ETF (NASDAQ:IBB) provides broader exposure to U.S. biotechnology and has been up around 25% year to date.